Penumbra Investor Alert: Kahn Swick & Foti Investigates Proposed Sale

Law firm examines adequacy of price and process in Penumbra's sale to Boston Scientific

Apr. 8, 2026 at 2:04am

Got story updates? Submit your updates here. ›

A photorealistic studio still life of polished stainless steel and glass medical device components arranged elegantly on a clean, monochromatic background, conceptually representing the complex financial and legal considerations behind a major corporate merger.A law firm's investigation into the proposed acquisition of a medical device maker highlights the need for transparency and fair value in major corporate deals.New Orleans Today

The law firm of Kahn Swick & Foti, LLC is investigating the proposed sale of medical device company Penumbra, Inc. to Boston Scientific Corporation. Under the terms, Penumbra shareholders would receive $374 in cash or 3.8721 shares of Boston Scientific stock per Penumbra share. KSF is seeking to determine if this consideration and the sale process are adequate or if the price undervalues Penumbra.

Why it matters

The investigation by KSF, led by former Louisiana Attorney General Charles C. Foti, Jr., aims to ensure Penumbra shareholders receive fair value in the proposed acquisition by Boston Scientific, one of the world's largest medical device companies.

The details

KSF is examining whether the terms of the proposed transaction, including the consideration to be paid to Penumbra shareholders, are proper. The firm is also looking into the sales process to determine if it was fair and maximized value for shareholders.

  • The proposed sale of Penumbra to Boston Scientific was announced on April 7, 2026.

The players

Kahn Swick & Foti, LLC

A law firm investigating the proposed sale of Penumbra to ensure shareholders receive fair value.

Charles C. Foti, Jr.

Former Attorney General of Louisiana and a partner at Kahn Swick & Foti, LLC.

Penumbra, Inc.

A medical device company that develops, manufactures and sells innovative products for the treatment of acute ischemic stroke.

Boston Scientific Corporation

A global medical device company that develops, manufactures and markets medical devices for a variety of clinical specialties.

Got photos? Submit your photos here. ›

What they’re saying

“If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn toll free at any time.”

— Lewis S. Kahn, Managing Partner, Kahn Swick & Foti, LLC

What’s next

KSF will continue its investigation into the proposed sale of Penumbra to Boston Scientific to determine if the terms are fair and maximize value for Penumbra shareholders.

The takeaway

This investigation by a prominent law firm highlights the importance of ensuring merger and acquisition deals are structured to provide fair value for shareholders, especially in the highly competitive medical device industry.